| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.23 | 93.9% | 58.7% |
| Total Income | 1.23 | 93.9% | 58.7% |
| Expenditure | 8.82 | 12.6% | 19.8% |
| PBT | -12.80 | 246.8% | 21.2% |
| Net Profit | -12.70 | 80.9% | 22.0% |
| OPM | — | ||
| NPM | — | ||
| EPS | -15.70 | 15.4% | 53.0% |
Jaguar Health Reports Q2 2026 Financials and Updates on Development Program
20 Aug 2026 · 20 Aug, 1:49 am
Summary
Jaguar Health reported its second-quarter 2026 financial results, with total revenue decreasing by 59% year-over-year to $1.225 million, primarily due to a 60% drop in prescription product revenue. Despite the revenue decline, the loss from operations saw a slight decrease of 5% to $7.597 million. The net loss attributable to common stockholders increased by 22% to $12.690 million. The company highlighted its ongoing global development program for crofelemer for rare intestinal failure diseases and anticipates the clinical package for the NDA for MVID to be ready by the end of 2026, with submission planned for Q2 2027.
Key Highlights
- 1
Jaguar Health reported its consolidated second-quarter 2026 financial results on August 19, 2026.
- 2
License and grant revenue for the second quarter of 2026 was $43,000, consistent with the prior year.
- 3
Prescription product revenue, net, was approximately $1.2 million in the second quarter of 2026, a decrease of 60% compared to the second quarter of 2025.
- 4
Total revenue, net, for the second quarter of 2026 was $1.225 million, a decrease of 59% compared to $2.979 million in the second quarter of 2025.
- 5
Loss from operations decreased by 5% to $7.597 million in the second quarter of 2026 from $8.007 million in the second quarter of 2025.
- 6
Net loss attributable to common stockholders increased by 22% to $12.690 million in the second quarter of 2026 from $10.407 million in the second quarter of 2025.
- 7
The company expects the clinical package for the NDA for crofelemer for MVID to be ready by the end of 2026, allowing submission of the NDA in Q2 2027.
Management Comments
Lisa A. Conte
The company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases. As announced, presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in patients with the ultrarare microvillus inclusion disease (MVID). The company expects the clinical package for the NDA for MVID to be ready by the end of 2026, allowing submission of the NDA in Q2 2027.
Informational and educational content only. Not investment advice.